Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CNMD 
CONMED Corporation (CNMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: CNMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $54
1 Year Target Price $54
| 0 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.07% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.37B USD | Price to earnings Ratio 21.63 | 1Y Target Price 54 |
Price to earnings Ratio 21.63 | 1Y Target Price 54 | ||
Volume (30-day avg) 6 | Beta 0.98 | 52 Weeks Range 40.16 - 75.30 | Updated Date 12/3/2025 |
52 Weeks Range 40.16 - 75.30 | Updated Date 12/3/2025 | ||
Dividends yield (FY) 1.82% | Basic EPS (TTM) 2.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 4.76% | Operating Margin (TTM) 10.84% |
Management Effectiveness
Return on Assets (TTM) 4.15% | Return on Equity (TTM) 6.6% |
Valuation
Trailing PE 21.63 | Forward PE 27.03 | Enterprise Value 2192897953 | Price to Sales(TTM) 1.02 |
Enterprise Value 2192897953 | Price to Sales(TTM) 1.02 | ||
Enterprise Value to Revenue 1.63 | Enterprise Value to EBITDA 11.45 | Shares Outstanding 30967954 | Shares Floating 30681810 |
Shares Outstanding 30967954 | Shares Floating 30681810 | ||
Percent Insiders 0.59 | Percent Institutions 114.22 |
Upturn AI SWOT
CONMED Corporation
Company Overview
History and Background
CONMED Corporation was founded in 1970. It has grown through product development and acquisitions, focusing on surgical devices and equipment.
Core Business Areas
- Orthopedic Surgery: Products for arthroscopic procedures, including resection, repair, and access. Includes brands like Linvatec.
- General Surgery: Devices for electrosurgery, endosurgery, and critical care. Includes brands like System 2450 and Argon Beam Coagulators.
Leadership and Structure
Curt R. Hartman is the Chairman of the Board, President, and CEO. The company has a standard corporate structure with functional departments.
Top Products and Market Share
Key Offerings
- Advanced Surgical: Includes advanced energy products (electrosurgical generators, ablation devices), endosurgical products (trocars, clip appliers), and smoke evacuation systems. Competitors include Medtronic and Johnson & Johnson. CONMED does not release specific market share percentages for these products.
- Orthopedics: Includes arthroscopic resection and repair systems, powered surgical instruments, and fluid management systems. Competitors include Stryker and Arthrex. CONMED does not release specific market share percentages for these products.
Market Dynamics
Industry Overview
The surgical device market is driven by aging populations, increasing surgical procedures, and technological advancements. It is highly competitive and regulated.
Positioning
CONMED is a mid-sized player in the surgical device market, focusing on niche segments and offering a comprehensive portfolio. They are known for innovation and customer service.
Total Addressable Market (TAM)
The global surgical devices market is estimated to be in the hundreds of billions of dollars. CONMED holds a smaller portion of this TAM compared to larger players like Medtronic, J&J, and Stryker but focuses on specialized areas.
Upturn SWOT Analysis
Strengths
- Broad product portfolio
- Strong brand recognition in specific surgical areas
- Established distribution network
- History of Innovation
Weaknesses
- Smaller market share compared to larger competitors
- Reliance on acquisitions for growth
- Potential supply chain vulnerabilities
- Higher debt levels
Opportunities
- Expanding into emerging markets
- Developing new technologies
- Acquiring complementary businesses
- Partnerships with hospitals and surgical centers
Threats
- Intense competition
- Pricing pressure
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- STRY
- BSX
Competitive Landscape
CONMED competes with larger companies with greater resources. CONMED is competitive in specific niche markets, like arthroscopic surgery and advanced surgical solutions.
Major Acquisitions
In2Bones SAS
- Year: 2024
- Acquisition Price (USD millions): 145
- Strategic Rationale: Expand global orthopedics portfolio with innovative extremity solutions, particularly in the foot and ankle segment
Biorez, Inc.
- Year: 2022
- Acquisition Price (USD millions): 85
- Strategic Rationale: Enhanced CONMEDu2019s Sports Medicine Portfolio, gaining access to BioRez's BioBrace Implant Technology
Growth Trajectory and Initiatives
Historical Growth: CONMED has grown through a combination of organic growth and acquisitions, expanding its product portfolio and market reach.
Future Projections: Analyst estimates vary, but generally project continued growth in revenue and earnings, driven by new product launches and market expansion.
Recent Initiatives: Recent strategic initiatives include acquisitions, product launches, and expansion of sales force.
Summary
CONMED Corporation is a mid-sized player in the surgical device market, focusing on orthopedics and general surgery. The company has a broad product portfolio and a history of innovation. However, CONMED faces intense competition and relies on acquisitions for growth. Continued focus on strategic acquisitions and innovation is crucial to maintain market position.
Similar Stocks
Sources and Disclaimers
Data Sources:
- CONMED Corporation Investor Relations
- Company SEC Filings (10K, 10Q)
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CONMED Corporation
Exchange NYSE | Headquaters Largo, FL, United States | ||
IPO Launch date 1987-07-23 | President, CEO & Director Mr. Patrick J. Beyer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 3900 | Website https://www.conmed.com |
Full time employees 3900 | Website https://www.conmed.com | ||
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures in the United States and internationally. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, the company offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention; and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.